Monthly injectable HIV treatment proves as effective as traditional daily pill regimen
pharmafile | July 24, 2017 | News story | Research and Development, Sales and Marketing | AIDS, HIV, Janssen, ViiV Healthcare, biotech, drugs, pharma, pharmaceuticals
New early trial data suggests that current daily HIV pill regimens could be replaced with injections which slowly release medication for the virus over time. This new method has been found to be as successful as current treatment plans and could provide the same benefits in just six injections annually.
Antiretroviral treatment suppresses the HIV virus and prevents it from developing into AIDS and has been pivotal in the recent decrease in AIDS-related deaths, with the number of fatalities decreasing by 50% since 2005 to around one million per year. Though current pill-based regimens are effective at tackling the disease, the treatment is a considerable burden, with patients forced to take up to tens of thousands of pills in their lifetime, and failure to adhere strictly to this can result in the virus resurfacing.
The new potential treatment combines existing HIV treatments cabotegravir and rilpivirine to be injected into muscle, which then slowly break down and release the medicines, providing long-term protection against the virus. It is of particular significance given that of the 36.7 million people infected with HIV worldwide, only 53% have access to the current standard of treatment.
The findings arose from a study of 309 HIV patients conducted at 50 research centres across the US, Canada, France, Spain and Germany. Once the virus had been controlled using oral therapy, these patients were treated with a traditional daily pill regimen, or monthly or bi-monthly injections. After 96 weeks, it was found that 84% of patients taking the oral pills still suppressed the virus, whereas compared to those who were administered with injections, 87% of those receiving it monthly still suppressed the virus, while 94% did the same in the bi-monthly group.
Dr David Margolis, a researcher from ViiV Healthcare – one of the funders of the study alongside Janssen – explained: “Adherence to medication remains an important challenge in HIV treatment. The introduction of single tablet medication represented a leap forward in antiretroviral therapy. Long-acting antiretroviral injections may represent the next revolution in HIV therapy by providing an option that circumvents the burden of daily dosing.”
Matt Fellows
Related Content
Gilead and Merck share data from phase 2 trial of HIV treatment
Gilead Sciences and Merck (known as MSD outside of the US and Canada) have announced …
ViiV Healthcare shares interim data from phase 3 trial for injectable HIV treatment
ViiV Healthcare has announced results from an interim analysis of the phase 3 LATITUDE trial, …
GSK enters agreement for license for JNJ-3089 for development of bepirovirsen
GSK and Arrowhead Pharmaceuticals have announced that they have come to an agreement with Janssen …
